Gladius Capital Management LP Cullinan Oncology, Inc. Transaction History

Gladius Capital Management LP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Dec 18, 2023	BUY	$8.8 - $13.4 $22,686 - $34,545	2,578 New	2,578 $27,000
Q2 2023 Aug 08, 2023	SELL	$8.8 - $13.4 $3,520 - $5,360	-400 Reduced 13.43%	2,578 $28,000
Q1 2023 Dec 18, 2023	BUY	$10.2 - $11.91 $30,375 - $35,467	2,978 New	2,978 $30,000
Q1 2023 May 09, 2023	SELL	$10.2 - $11.91 $163 - $190	-16 Reduced 0.53%	2,978 $31,000
Q4 2022 Dec 18, 2023	BUY	$9.72 - $13.62 $29,101 - $40,778	2,994 New	2,994 $31,000
Q4 2022 Feb 02, 2023	BUY	$9.72 - $13.62 $2,332 - $3,268	240 Added 8.71%	2,994 $32,000
Q3 2022 Nov 14, 2022	BUY	$11.82 - $15.42 $32,552 - $42,466	2,754 New	2,754 $36,000

146

67.6M

612K

118K

Ticker CGEM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,612,200
Market Cap $499M
Description
Cullinan Oncology Inc., a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company's lead candidate is the CLN-081, an orally available small molecule that is in a Phase I/IIa dose escalation and expansion trial for treating patients with ...

Get notified when there are updates to the investment portfolio of Gladius Capital Management LP, based on Form 13F filings with the SEC.

Stay updated on Gladius Capital Management LP with notifications on news.